Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Hikal has reported results for fourth quarter and year ended March 31, 2017.
The company has reported a rise of 23.28% in its net profit at Rs 27.43 crore for the quarter ended March 31, 2017 as compared to Rs 22.25 crore for the same quarter in the previous year. Total income of the company increased by 7.11% at Rs 310.75 crore for quarter under review as compared to Rs 290.12 crore for the quarter ended March 31, 2016.
For the year ended March 31, 2017, the company has posted a jump of 61.67% in its net profit at Rs 66.80 crore as compared to Rs 41.32 crore in FY16. Total income of company increased by 9.69% at Rs 1017.38 crore for year under review as compared to Rs 927.49 crore for the year ended March 31, 2016.
For the year ended March 31, 2017, on the consolidated basis, the company has posted a rise of 55.11% in its net profit at Rs 63.89 crore as compared to Rs 41.19 crore in FY16. Total income of company increased by 9.69% at Rs 1017.38 crore for year under review as compared to Rs 927.49 crore for the year ended March 31, 2016.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1692.70 |
Dr. Reddys Lab | 1153.30 |
Cipla | 1499.40 |
Lupin | 1939.05 |
Zydus Lifesciences | 826.20 |
View more.. |